Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions

British Medical Journal

Volumn 316, Issue 7131, 1998, Pages 589-592

  De Bruijnj Stam, S F T M ^a,b   Koopman, M M W ^a   Vandenbroucke, J P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S;

ADULT; ANTITHROMBIN DEFICIENCY; ARTICLE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CAVERNOUS SINUS THROMBOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; NETHERLANDS; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; BLOOD COAGULATION DISORDERS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FACTOR V; FEMALE; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; RISK FACTORS; SINUS THROMBOSIS, INTRACRANIAL;

EID: 0032554293     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1575-82.
2. Vandenbroucke JP, Koster T, Briet E, Rcitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lanfft 19943-14:1453-7.
3. Bousser M, Chiras J, Bories J, Castaigne P. Cerebral venous thrombosis: a review of 38 cases. Stroke 1985;16:199-213.
4. Deschiens MA, Conard J, Horellou MH, Ameri A, Preter M, Chedru F, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996;27:1724-30.
5. Peters M, Brecderveld C, Kahle LI I, ten Cate JW Rapid microanalysis of coagulation parameters by automated chromogenic substrate methods, application in neonatal patients. Ttiromb Res 19S2;28:773-81.
6. Boyer C, Rothschild C, Wolf M, Amiral J, Meyer D, Larrieru M. A new method of estimation of protein C by ELISA. Thromb Res 1984;3G: 579-89.
7. Deutz-Terlouw PP, Ballering L, Wijngaarden vA, Bertina RM. Two ELlSAs for measurement of protein S, and their use in the laboratory diagnosis of protein S deficiency. Clin ChimAda 1989:186:321.
8. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sei USA 1993:90:1001-8.
9. Voorberg J, Roelse J, Koopman R. Association of idiopathic venous thromboembolism with single point mutation at Arg 50G of factor V. Lancet 199I;343:1535-6.
10. CBS; Nederlands Insiituut voor onderzoek van de Ecrstclijnsgezondheidszorg: Inspectie voor de Gezondheidszorg. Enkele vormen van geboortenregeling. In: Ceiitraal Bureau i-oorde Statistiek. Statistisch jaarboek 1996 The Hague: SDU, 1996:502.
11. Statistics Netherlands. Netherlands health interview survey 1981-1995. The Hague: SOU, 1996.
12. Rothman KJ. Modern epidemiology. Boston: Little, Brown, 1986.
13. Ridker I'M, Miletich JP, Hennekkens CH, BuringJE. Ethnic distribution of factor V 'Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAWA 1997;277:1305-7.
14. Hach-Wunderle V, Scharrer I. Pravalenz des hereditaren Mangels an Antitlirombin III, Protein C und Protein S. Deutschen Medischen Wobchenschrift mS;l 18:187-90.
15. Tait RC, Walker ID, Reitsma PH, Islam SI, McCalI F, Poort SR, et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995;73:87-93.
16. Kalbag RM, Woolf AL. Cerebral venous thrombosis. London: Oxford University Press, 1967.
17. Realini JP, GoldzieherJW. Oral contraceptives and cardiovascular disease: a critique of the epidemiologic studies. AmJ Obstet Gynecol 1985;152: 729-98.
18. Dormont D, Anxionnat C, Evrard S, Louaille C, CliirasJ, Marsault C. MRI in cerebral venous thrombosis.yAVurora/fto/1994:21:81-99.
19. Buchanan LTCDS, Brazinsky MAJJH. Durai sinus and cerebral venous thrombosis incidence in young women receiving oral contraceptives. Areh Neural 1970:22:440-4.
20. Martinelli I, Landi G, Merati G, Cella R,Tosetto A, Mannucci P.M. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996:75:393-4.
21. Martinelli I, Rosendaal FR, Vandcnbroucke JP, Mannucci P.M. Oral contraceptives are a risk factor for cerebral vein thrombosis [letter]. Thromb Haemost 1996:76:477-8.
22. Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, van der Ploeg PM, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third generation oral contraceptives. BrJ Hatmatol 1997;97:233-8.
23. Zuber M, Toulon P, Marnet L, Mas}. Factor V Leiden mutation in cerebral venous thrombosis. Stroke 1996;27:1721-3.
24. Krayenbuld HA. Cerebral venous and sinus thrombosis. Clin Neurosurg 1966;14:l-24. (Accepted 11 Navember 1997)